{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:16:15Z","timestamp":1778660175414,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Yin Shu-Tien Foundation, Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program","award":["114-V-B-047"],"award-info":[{"award-number":["114-V-B-047"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Boron neutron capture therapy (BNCT) presents a targeted re-irradiation strategy for recurrent glioblastoma. However, its survival benefit remains unclear, as few studies have compared the addition of BNCT to bevacizumab (BEV) with BEV alone or other salvage approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 171 adults with recurrent glioblastoma: 116 treated with BEV \u00b1 chemotherapy (control group) and 55 treated with BNCT plus BEV \u00b1 chemotherapy (BNCT group). To improve comparability, propensity score matching was performed using age, performance status, recurrent tumor volume, recurrence-to-salvage-treatment interval, the number of relapses, re-resection, and chemotherapy use. Survival outcomes were assessed using Kaplan-Meier estimates and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the matched cohort (n\u2009=\u200998), progression-free survival (PFS) was significantly longer in the BNCT group compared with the control group (median 5.34 vs 3.70 months, hazard ratio [HR]: 0.54, P\u2009=\u2009.026), whereas overall survival (OS) was comparable (HR: 0.86, P\u2009=\u2009.524). The objective response rate was significantly higher in the BNCT group compared with the control group (67.4% vs 47.0%; P\u2009=\u2009.041). Multivariable analysis showed that the absence of callosal involvement (odds ratio [OR]: 0.10, P\u2009=\u2009.033) and higher minimum absorbed dose (OR: 1.09; P\u2009=\u2009.028) were independently associated with better BNCT response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Boron neutron capture therapy plus BEV was associated with higher objective response rate and improved PFS compared with BEV alone in patients with recurrent glioblastoma, although no OS difference was demonstrated. These findings support BNCT as a salvage strategy but warrant prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag013","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:18:38Z","timestamp":1768825118000},"source":"Crossref","is-referenced-by-count":0,"title":["Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score\u2013matched analysis"],"prefix":"10.1093","volume":"8","author":[{"given":"Shuo-Fu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1110-6174","authenticated-orcid":false,"given":"Yi-Yen","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-4731","authenticated-orcid":false,"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]},{"name":"Department of Oncology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"Division of Transfusion Medicine, Department of Medicine, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Fu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanford P C","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Chi","family":"Chang","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]},{"name":"Department of Radiology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chun","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]},{"name":"Department of Radiology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Chieh","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital ,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko-Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Cheng","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology , Hsinchu City,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinn-Jer","family":"Peir","sequence":"additional","affiliation":[{"name":"Department of Nuclear Science & Technology Development, National Tsing-Hua University , Hsinchu City,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fong-In","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Science & Technology Development, National Tsing-Hua University , Hsinchu City,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Institute for Integrated Radiation and Nuclear Science, Kyoto University , Kumatori, Osaka,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital , Taipei,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei,","place":["Taiwan"]},{"name":"Department of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology , Hsinchu City,","place":["Taiwan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026051304011834500_vdag013-B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026051304011834500_vdag013-B2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14737140.2020.1807949","article-title":"Treatment of recurrent glioblastoma: state-of-the-art and future perspectives","volume":"20","author":"Di Nunno","year":"2020","journal-title":"Expert Rev Anti\u00adcancer Ther"},{"key":"2026051304011834500_vdag013-B3","doi-asserted-by":"publisher","first-page":"vdab052","DOI":"10.1093\/noajnl\/vdab052","article-title":"Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma","volume":"3","author":"Schritz","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026051304011834500_vdag013-B4","doi-asserted-by":"publisher","first-page":"110696","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiotherapy and Oncology"},{"key":"2026051304011834500_vdag013-B5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s11060-017-2477-x","article-title":"The role of bevacizumab in the treatment of glioblastoma","volume":"133","author":"Diaz","year":"2017","journal-title":"J Neurooncol"},{"key":"2026051304011834500_vdag013-B6","doi-asserted-by":"publisher","first-page":"110437","DOI":"10.1016\/j.radonc.2024.110437","article-title":"Re-irradiation treatment regimens for patients with recurrent glioma\u2014evaluation of the optimal dose and best concurrent therapy","volume":"199","author":"Fleischmann","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026051304011834500_vdag013-B7","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026051304011834500_vdag013-B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-020-03586-6","article-title":"Boron neutron capture therapy for malignant brain tumors","volume":"149","author":"Miyatake","year":"2020","journal-title":"J Neurooncol"},{"key":"2026051304011834500_vdag013-B9","doi-asserted-by":"publisher","first-page":"115103","DOI":"10.1016\/j.bcp.2022.115103","article-title":"LAT1, a novel pharmacological target for the treatment of glioblastoma","volume":"201","author":"Cappoli","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"2026051304011834500_vdag013-B10","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1158\/0008-5472.CAN-08-2345","article-title":"L-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors","volume":"69","author":"Detta","year":"2009","journal-title":"Cancer Res"},{"key":"2026051304011834500_vdag013-B11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3892\/ijmm.2025.5611","article-title":"L-type amino acid transporter 1 in enhancing boron neutron capture therapy: mechanisms, challenges and future directions","volume":"56","author":"Zheng","year":"2025","journal-title":"Int J Molec Med"},{"key":"2026051304011834500_vdag013-B12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/jrr\/rrac077","article-title":"Correlation between the expression of LAT1 in cancer cells and the potential efficacy of boron neutron capture therapy","volume":"64","author":"Watanabe","year":"2023","journal-title":"J Radiat Res"},{"key":"2026051304011834500_vdag013-B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1269\/jrr.08043","article-title":"Boron neutron capture therapy for newly diagnosed glioblastoma","volume":"50","author":"Kawabata","year":"2009","journal-title":"J Radiat Res"},{"key":"2026051304011834500_vdag013-B14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/neuonc\/noab108","article-title":"Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up","volume":"24","author":"Takai","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026051304011834500_vdag013-B15","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high-and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026051304011834500_vdag013-B16","doi-asserted-by":"publisher","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026051304011834500_vdag013-B17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.002","article-title":"Evidence-based recommendations on categories for extent of resection in diffuse glioma","volume":"149","author":"Karschnia","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026051304011834500_vdag013-B18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1227\/NEU.0b013e318223f5a7","article-title":"Application of novel response\/progression measures for surgically delivered therapies for gliomas: response assessment in Neuro-Oncology (RANO) working group","volume":"70","author":"Vogelbaum","year":"2012","journal-title":"Neurosurgery"},{"key":"2026051304011834500_vdag013-B19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3171\/2020.7.JNS201362","article-title":"Effects of ventricular entry on patient outcome during glioblastoma resection","volume":"135","author":"Young","year":"2021","journal-title":"J Neurosurg"},{"key":"2026051304011834500_vdag013-B20","volume-title":"Advances in Boron Neutron Capture Therapy","year":"2023"},{"key":"2026051304011834500_vdag013-B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-008-9699-x","article-title":"Survival benefit of boron neutron capture therapy for recurrent malignant gliomas","volume":"91","author":"Miyatake","year":"2009","journal-title":"J Neurooncol"},{"key":"2026051304011834500_vdag013-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1748-717X-9-130","article-title":"Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide","volume":"9","author":"Gebhardt","year":"2014","journal-title":"Radiat Oncol"},{"key":"2026051304011834500_vdag013-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"2026051304011834500_vdag013-B24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2176\/nmc.ra.2015-0297","article-title":"Boron neutron capture therapy for malignant brain tumors","volume":"56","author":"Miyatake","year":"2016","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"2026051304011834500_vdag013-B25","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.216","article-title":"Target volume delineation for the re-irradiation of recurrent glioblastoma: MRI-or PET-based? Results of the GLIAA prospective randomized trial","volume":"120","author":"Popp","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026051304011834500_vdag013-B26","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00432-020-03187-w","article-title":"Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma","volume":"146","author":"Scartoni","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026051304011834500_vdag013-B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.14338\/THEIJPT-14-00029.1","article-title":"Reirradiation with proton therapy for recurrent gliomas","volume":"2","author":"Galle","year":"2015","journal-title":"Int J Part Ther"},{"key":"2026051304011834500_vdag013-B28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.adro.2020.03.022","article-title":"Clinical outcomes in patients with recurrent glioblastoma treated with proton beam therapy reirradiation: analysis of the multi-institutional proton collaborative group registry","volume":"5","author":"Saeed","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2026051304011834500_vdag013-B29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/1471-2407-10-533","article-title":"Randomised phase I\/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial","volume":"10","author":"Combs","year":"2010","journal-title":"BMC Cancer"},{"key":"2026051304011834500_vdag013-B30","doi-asserted-by":"publisher","first-page":"101465","DOI":"10.1016\/j.adro.2024.101465","article-title":"Review of recent improvements in carbon ion radiotherapy in the treatment of glioblastoma","volume":"9","author":"Koosha","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"2026051304011834500_vdag013-B31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00066-021-01844-8","article-title":"Comparison of carbon ion and photon reirradiation for recurrent glioblastoma","volume":"198","author":"Lautenschlaeger","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"2026051304011834500_vdag013-B32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jjco\/hyac004","article-title":"Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma","volume":"52","author":"Furuse","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2026051304011834500_vdag013-B33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4143\/crt.2014.259","article-title":"Hypofractionated stereotactic radiation therapy in recurrent high-grade glioma: a new challenge","volume":"48","author":"Navarria","year":"2016","journal-title":"Cancer Res Treat"},{"key":"2026051304011834500_vdag013-B34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.radonc.2015.11.017","article-title":"Adverse prognosis and distinct progression patterns after concurrent chemoradiotherapy for glioblastoma with synchronous subventricular zone and corpus callosum invasion","volume":"118","author":"Liang","year":"2016","journal-title":"Radiother Oncol"},{"key":"2026051304011834500_vdag013-B35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijrobp.2010.02.031","article-title":"L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a phase I study","volume":"80","author":"Kankaanranta","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026051304011834500_vdag013-B36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1600-0404.2007.00924.x","article-title":"An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme","volume":"117","author":"Pellettieri","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"2026051304011834500_vdag013-B37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-023-04441-0","article-title":"Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity","volume":"164","author":"Marwah","year":"2023","journal-title":"J Neurooncol"},{"key":"2026051304011834500_vdag013-B38","doi-asserted-by":"publisher","first-page":"vdab067","DOI":"10.1093\/noajnl\/vdab067","article-title":"Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study","volume":"3","author":"Kawabata","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026051304011834500_vdag013-B39","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/j.1582-4934.2009.00856.x","article-title":"EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research\/phase 1 trial","volume":"13","author":"Wittig","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2026051304011834500_vdag013-B40","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.21037\/qims-23-1769","article-title":"Prognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors","volume":"14","author":"Lin","year":"2024","journal-title":"Quant Imaging Med Surg"},{"key":"2026051304011834500_vdag013-B41","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1016\/j.ijrobp.2020.07.764","article-title":"Tumor 18F-BPA uptake in PET and boron neutron capture therapy efficacy in locally recurrent head and neck cancer","volume":"108","author":"Koivunoro","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026051304011834500_vdag013-B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/tro.2018.10.08","article-title":"A brief review on reactor-based neutron sources for boron neutron capture therapy","volume":"2","author":"Altieri","year":"2018","journal-title":"Ther Radiol Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag013\/66560630\/vdag013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag013\/68277342\/vdag013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag013\/68277342\/vdag013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:01:25Z","timestamp":1778659285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag013\/8439751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag013","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag013"}}